Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2019-11-08
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of tivozanib and to see how well
it works in treating patients with liver cancer that has spread to other parts of the body or
cannot be removed by surgery. Tivozanib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
AVEO Pharmaceuticals, Inc. National Cancer Institute (NCI) National Comprehensive Cancer Network